TTX Shares Tetratherix Limited
ACCUMULATE ASX · ASXBiomaterials pipeline milestones and healthcare-sector rotation provide speculative catalyst-driven upside.
Future value: $6.95 (+29.84%) · 6-12 months · analyst consensus
Signal breakdown
- ▸Upcoming clinical and regulatory milestones
- ▾Below 50-day MA (-15.92%)
- ▸~30% upside to price target
Is TTX a buy right now?
Trend: TTX is trading below the 50-day average (-15.67%), RSI 57 — neutral momentum, with a 3-month return of -28.12%.
Valuation & quality: Tetratherix Limited trades on forward P/E -41.3, price-to-book 8.68; fundamentals show net margin -241.4%, return on equity -31.1%, revenue growth 313.9% year on year.
Analyst consensus: 3 analysts have a mean 12-month price target of A$6.95 (+29.8% vs the last close; range A$5.30 – A$8.59), consensus rating “buy”.
Our screen: ACCUMULATE (score 1) — Biomaterials pipeline milestones and healthcare-sector rotation provide speculative catalyst-driven upside.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| +8.80% | +14.00% | +52.30% | -17.90% | +24.20% | -4.00% | -11.90% | -14.90% |
Fundamentals
Analyst price target
Technical signals
About Tetratherix Limited
Tetratherix Limited engages in biomaterial and regenerative medicine business in Australia and internationally.
Sector: Healthcare · Industry: Biotechnology · Australia · 25 employees · Website
Related Health Care picks
Browse: all ASX stocks · Health Care picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.